ABUS — Arbutus Biopharma Corp
$4.20-0.24%
Last close: · regular session
After-hours $4.21 +0.24% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ABUS in the TickerWise workspace.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 44
- Website: http://www.arbutusbio.com
Latest SEC filings for ABUS
Latest ABUS news
- Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.3% – Here’s What Happened Read article
- Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer Read article
- Arbutus gains on plans to buy back 46M shares in tender offer Read article
- Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.